Commercial Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool pharminent April 17, 2026
Commercial Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch pharminent April 17, 2026
Commercial Revolution doubles stock offering target to $2B following pancreatic cancer win pharminent April 16, 2026
Commercial With nearly a quarter billion in Q1, J&J targets $100B revenue in 2026 pharminent April 14, 2026
Commercial With oral obesity race underway, all eyes are on Lilly’s Foundayo launch pharminent April 10, 2026
Commercial Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk pharminent April 9, 2026
Commercial Approvals in Hand, Lilly and Novo Obesity Pills Will Battle It Out on Hairline Differences pharminent April 2, 2026
